Pfizer Stock: The Truth About Its Dividend

AI-generated source summary

Pfizer (PFE) is currently trading at approximately $27.66. The analysis suggests a potential upside to $32.00, indicating an estimated 16% potential return. This valuation is supplemented by a ~6% dividend yield. However, significant risks are identified. The company faces patent expirations on key drugs like Eliquis, Vyndaqel, Ibrance, and Xtandi between 2026 and 2030, which account for approximately 34% of revenue. Volatile demand for COVID-19 products (Comirnaty and Paxlovid) represents an additional 11% of revenue, due to unpredictable baseline demand. The remaining 55% of revenue comes from relatively safer core products like Prevnar 20, Nurtec, and Seagen oncology drugs. The company carries a substantial debt load of $67 billion, though this is considered manageable with current interest payments. Free cash flow generation is estimated at $11.08 billion, with $9.88 billion paid out in dividends annually, resulting in a payout ratio of approximately 89%. A 15% drop in free cash flow, due to patent losses without immediate pipeline replacements, would lead to a deficit in dividend coverage. Recent insider buying, with directors and officers purchasing approximately $1 million each in stock, suggests confidence from within. However, the reliance on new drug development and pipeline success to offset patent cliffs is a critical factor. Given the high patent risk and the debt load, despite the potential upside and insider buying, the current recommendation is 'not buying'.

AI-generated summary based on the source content.